Literature DB >> 11927286

Therapeutic exploitation of the p53 pathway.

David P Lane1, Sonia Lain.   

Abstract

Analysis of the gene encoding p53 could serve to evaluate the effectiveness of a cancer treatment. Mutations in this gene occur in half of all human cancers, and regulation of the protein is defective in a variety of others. Novel strategies that exploit our knowledge of the function and regulation of p53 are being actively investigated. Strategies directed at treating tumours that have p53 mutations include gene therapy, viruses that only replicate in p53 deficient cells, and the search for small molecules that reactivate mutant p53. Potentiating the function of p53 in a non-genotoxic way in tumours that express wildtype protein can be achieved by inhibiting the expression and function of Mdm2 or viral oncoproteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927286     DOI: 10.1016/s1471-4914(02)02309-2

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  20 in total

1.  CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90.

Authors:  Stefan Rudiger; Stefan M V Freund; Dmitry B Veprintsev; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-05       Impact factor: 11.205

2.  Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways.

Authors:  Luis Alfonso Martinez; Irina Naguibneva; Heike Lehrmann; Arlette Vervisch; Thierry Tchénio; Guillermina Lozano; Annick Harel-Bellan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-28       Impact factor: 11.205

3.  The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.

Authors:  Zhu Yuan; Kang Cao; Chao Lin; Lei Li; Huan-yi Liu; Xin-yu Zhao; Lei Liu; Hong-xin Deng; Jiong Li; Chun-lai Nie; Yu-quan Wei
Journal:  Mol Med       Date:  2011-08-19       Impact factor: 6.354

4.  MDM2 is required for suppression of apoptosis by activated Akt1 in salivary acinar cells.

Authors:  Kirsten H Limesand; Kathryn L Schwertfeger; Steven M Anderson
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

Review 5.  Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Authors:  Michelle Martinez-Rivera; Zahid H Siddik
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

6.  Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide.

Authors:  Natalia Issaeva; Assaf Friedler; Przemyslaw Bozko; Klas G Wiman; Alan R Fersht; Galina Selivanova
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

Review 7.  Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy.

Authors:  Nikolina Vlatković; Mark T Boyd; Carlos P Rubbi
Journal:  Cell Mol Life Sci       Date:  2013-05-18       Impact factor: 9.261

8.  Selective killing of Smad4-negative tumor cells via a designed repressor strategy.

Authors:  Vidula Dixit; Rudy L Juliano
Journal:  Mol Pharmacol       Date:  2008-04-21       Impact factor: 4.436

9.  Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Authors:  Shunsuke Kato; Shuang-Yin Han; Wen Liu; Kazunori Otsuka; Hiroyuki Shibata; Ryunosuke Kanamaru; Chikashi Ishioka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 11.205

10.  [Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53].

Authors:  D V Kochetkov; G V Il'inskaia; P G Komarov; E Strom; L S Agapova; A V Ivanov; A V Budanov; E I Frolova; P M Chumakov
Journal:  Mol Biol (Mosk)       Date:  2007 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.